Rautoma P, Erkola O, Meretoja O A
Maria Hospital, University of Helsinki, Finland.
Acta Anaesthesiol Scand. 1995 Feb;39(2):220-3. doi: 10.1111/j.1399-6576.1995.tb04047.x.
A synergism exists between some competitive muscle relaxants. However, maintenance requirement of a combination of muscle relaxants has been evaluated only in paediatric patients. We studied 45 elective adult surgical patients (ASA I-II) during propofol-alfentanyl-N2O-O2-anaesthesia. The first 30 patients were randomized to receive either atracurium or vecuronium to create individual dose-response curves for these muscle relaxants. ED95-values for atracurium and vecuronium were 260 +/- 9 and 59 +/- 3 micrograms.kg-1, respectively (mean +/- s.e. mean). Requirements of atracurium and vecuronium to maintain an 85-95% neuromuscular blockade were 301 and 83 micrograms kg-1 h-1, respectively. An additional 15 patients received a combination of atracurium and vecuronium (cAV) in an equipotent dose ratio. An ED95 of a cAV was 94 +/- 7 micrograms.kg-1 of atracurium together with 21 +/- 2 micrograms.kg-1 of vecuronium, or 72 +/- 6% of one ED95 dose of a parent agent. Potentiation was significant (P = 0.0001). A maintenance requirement of a cAV was 120 micrograms kg-1 h-1 of atracurium together with 27 micrograms kg-1 h-1 of vecuronium. Thus, a significant potentiation was maintained also during the course of anaesthesia. A cAV had an effect like one intermediate-acting agent. If a cAV is used instead of using atracurium or vecuronium alone, the maximal reduction of drug consumption would be approximately 30%.
某些竞争性肌肉松弛剂之间存在协同作用。然而,肌肉松弛剂联合使用时的维持剂量需求仅在儿科患者中进行过评估。我们在丙泊酚-阿芬太尼-N₂O-O₂麻醉期间研究了45例择期成年手术患者(ASA I-II级)。前30例患者被随机分为接受阿曲库铵或维库溴铵,以建立这些肌肉松弛剂的个体剂量-反应曲线。阿曲库铵和维库溴铵的ED95值分别为260±9和59±3微克·kg⁻¹(均值±标准误均值)。维持85%-95%神经肌肉阻滞所需的阿曲库铵和维库溴铵剂量分别为301和83微克·kg⁻¹·h⁻¹。另外15例患者接受了等效能剂量比的阿曲库铵和维库溴铵联合用药(cAV)。cAV的ED95为94±7微克·kg⁻¹的阿曲库铵与21±2微克·kg⁻¹的维库溴铵,或一种母体药物一个ED95剂量的72±6%。协同作用显著(P = 0.0001)。cAV的维持剂量需求为120微克·kg⁻¹·h⁻¹的阿曲库铵与27微克·kg⁻¹·h⁻¹的维库溴铵。因此,在麻醉过程中也维持了显著的协同作用。cAV的作用类似于一种中效药物。如果使用cAV而不是单独使用阿曲库铵或维库溴铵,药物消耗量的最大减少量约为30%。